Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 13Recruiting 5Active not recruiting 3Unknown 1Terminated 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Lymphoid 1

Conditions

Prostatic Neoplasms 2Waldenstrom Macroglobulinemia 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Valacyclovir × Clear all
NCT00492050 2026-03-11

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
46 enrolled 10 charts
Lymphoid

Waldenstrom Macroglobulinemia

NCT01436968 2025-07-30

PrTK03

Candel Therapeutics, Inc.

Phase 3 Active not recruiting
711 enrolled
Genitourinary

Prostatic Neoplasms

NCT02768363 2025-07-30

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

Candel Therapeutics, Inc.

Phase 2 Active not recruiting
187 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡